Arbutus Announces Abstract Selected for Publication at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
WARMINSTER, Pa., May 26, 2022 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage…
News
Affimed Highlights Trial Designs of Three AFM24 Ongoing Clinical Studies at the Annual Meeting of the American Society of Clinical Oncology (ASCO)
Design and rationale of the phase 1/2a open label, multicenter study of the AFM24 monotherapy…
Mereo BioPharma Announces the Presentation of Updated Data From a Phase 1b/2 Study of Etigilimab as a Poster at the 2022 American Society of Clinical Oncology Annual Meeting
Phase 1b/2 Study of Etigilimab and Nivolumab in Subjects with Select Locally Advanced or Metastatic…
PDS Biotech Announces Presentation of Efficacy and Safety Data from VERSATILE-002 Phase 2 Clinical Trial in Recurrent or Metastatic Head and Neck Cancer at ASCO 2022
Preliminary data from first 19 patients treated with PDS0101 in combination with KEYTRUDA® (pembrolizumab) demonstrates…
PDS Biotech Announces Presentation of Data from NCI-Led Triple Combination Phase 2 Clinical Trial in Advanced, Refractory HPV-Positive Cancers at ASCO 2022
77% of checkpoint inhibitor (CPI) refractory patients alive at median follow up of 12 months…
University of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) — Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company…
Galera Announces Oral Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Detailing Results from Phase 3 ROMAN Trial of Avasopasem
Avasopasem produced clinically meaningful, statistically significant reduction of severe oral mucositis (SOM) in patients with…
Cue Biopharma to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
BOSTON, May 26, 2022 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical…
Rubius Therapeutics to Present Trials in Progress Poster for the Phase 1/2 Clinical Trial of RTX-224 in Select Advanced Solid Tumors at the 2022 American Society of Clinical Oncology Annual Meeting
CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) — Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical…
Advaxis to Present Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in Metastatic Non-Small-Cell Lung Cancer (NSCLC) and Study Design of ADXS-504 Trial in Early Prostate Cancer at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
Overall response rate of 14% and disease control rate of 36% in Part B of…
Kinnate Biopharma Inc. to Present Trial Design for its Pan-FGFR Inhibitor Product Candidate, KIN-3248, at ASCO 2022
Preclinical data from a study of the Company’s pan-RAF product candidate, KIN-2787, in combination with…
Harpoon Presents Interim Data from Ongoing Dose Escalation Portion of T Cell Engager HPN328 Clinical Trial at 2022 ASCO Annual Meeting
Clinically active and well tolerated in patients with solid tumors Favorable safety profile emerging: 22%…
IO Biotech Announces Two Presentations at the American Society of Clinical Oncology Annual Meeting 2022
NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical…
Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody® ADG126, with Repeat Dosing Across Dose Levels
– First clinical data demonstrating potential of SAFEbody technology platform to create…
Data from SOTIO’s Phase 1/1b AURELIO-03 Trial of SOT101 Demonstrate Clinical Benefit in Patients with Solid Tumors
Data demonstrate that SOT101 monotherapy and SOT101 in combination with pembrolizumab have a favorable safety…
Surface Oncology to Present New SRF388 Clinical Data at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
– SRF388 demonstrated clinical activity in multiple solid tumor types withthree confirmed partial responses across…
NKGen Biotech To Present SNK01 Clinical Data at the 2022 ASCO Annual Meeting
SANTA ANA, Calif., May 26, 2022 (GLOBE NEWSWIRE) — NKGen Biotech Inc., a biotechnology company…
Elevar Therapeutics Announces Rivoceranib Demonstrated Clinical Effectiveness in Patients with Progressive Recurrent or Metastatic Adenoid Cystic Carcinoma in a Phase 2 Trial
Results of open-label, multicenter study will be presented during a poster session at ASCO on…
Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Media Release Copenhagen, Denmark, May 26, 2022 Multiple epcoritamab (DuoBody®-CD3xCD20) poster presentations highlighting data in…
Tempest Reports Positive TPST-1120 Clinical Data from Phase 1 Trial in Patients with Advanced Solid Tumors at 2022 ASCO Annual Meeting
RECIST responses observed in IO-refractory patients and in IO-resistant indications 30% ORR in patients treated…